Millennium Pharmaceuticals, Inc.

Cambridge, MA 02139

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $0.0
First Award Date 06/01/95
Most Recent Award Date 01/01/99

Key Personnel

Last Name Name Awards Contact
Koltin Yigal Koltin 4
An Zhiqiang An 2
Timberlake William E Timberlake 1

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/99 - 12/31/99

During Phase I, we have developed a novel technology to capture the genetic diversity from unculturable fungi for drug discovery. Briefly, large segments of genomic DNA from unculturable fungi are cloned and introduced in genetically amenable laboratory strains. By doing this, we ask the laboratory s...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/98 - 11/30/98

DESCRIPTION: (Abstract of the applicant): Filamentous fungi are the richest known source of polyketides, secondary metabolites of proved pharmaceutical value that possess enormous potential for identification of new drugs. The goal of this proposal is to adapt recently developed genetic technology to f...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/98 - 12/31/98

During Phase I, we have developed a novel technology to capture the genetic diversity from unculturable fungi for drug discovery. Briefly, large segments of genomic DNA from unculturable fungi are cloned and introduced in genetically amenable laboratory strains. By doing this, we ask the laboratory s...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 03/31/98

This proposal seeks to discover novel immunosuppressants that selectively regulate cytokine production by myeloid and lymphoid cells. The search will be directed by the application of Millennium Pharmaceuticals' QuickScan TM, a proprietary collection of extracts from phylogenetically diverse and productive ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/97 - 07/31/97

There is an urgent need for new therapeutic drugs in many therapeutic areas. Millennium Pharmaceuticals was established to meet these challenges using fungal secondary metabolites as a major drug source. Traditionally, fungi that have been selected for drug screening are those that can be easily cultured in the ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/95 - 08/31/96

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/95 - 12/31/95

The study's objectives are to establish means to discover agents effective against fungal topoisomerases I and II. Long-term objectives are to implement a cell-based target-oriented search for inhibitors of topoisomerases of pathogenic fungi with complementary enzyme-based assays. Towards this effort Myc...